AKBLF On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
Berlin
OTC US
text size: T | T
Back to Snapshot
Company Description

Contact Info

Bøge Allé 6-8

Hørsholm, 2970

Denmark

Phone: 45 45 74 75 76

Fax: 45 45 74 86 90

ALK-Abelló A/S, a pharmaceutical company, develops, manufactures, and sells a range of products for the diagnosis and treatment of respiratory diseases worldwide. The company offers allergy immunotherapy products, such as subcutaneous injections under the Alutard SQ and AVANZ brand names; sublingual drops under the SLIToneULTRA and Osiris brand names; and sublingual tablets under the GRAZAX/GRASTEK, RAGWITEK, and ACARIZAX/MITICURE brand names. Its allergy immunotherapy products are used for treating various allergies, including grass, ragweed, house dust mite, tree, Japanese cedar, and cat, as well as bee and wasp venom. The company also offers adrenaline auto-injectors for the treatment of severe allergic reactions. It has strategic partnership agreements with Merck & Co., Inc. and Torii Pharmaceutical Co., Ltd. to develop, register, and commercialize SLIT-tablets in North America and Japan. The company was founded in 1923 and is headquartered in Hørsholm, Denmark.

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

AKBLF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKBLF.
View Industry Companies
 

Industry Analysis

AKBLF

Industry Average

Valuation AKBLF Industry Range
Price/Earnings 23.5x
Price/Sales 3.3x
Price/Book 3.3x
Price/Cash Flow 22.1x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ALK-ABELLO A/S, please visit www.alk-abello.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.